Search results
Results From The WOW.Com Content Network
Biogen is a leading global biotechnology company that pioneers science and drives innovations for complex and devastating diseases. Biogen is advancing a pipeline of potential therapies across neurology, neuropsychiatry, specialized immunology and rare disease and remains acutely focused on its purpose of serving humanity through science while ...
Founded in 1978, Biogen has pioneered multiple breakthrough innovations including a broad portfolio of medicines to treat multiple sclerosis, the first approved treatment for spinal muscular atrophy, and two co-developed treatments to address a defining pathology of Alzheimer’s disease.
Everyone at Biogen contributes to our mission to create transformative medicines for people who need them the most. Explore our business areas to discover where you can make an impact on our team.
With a strong focus on difficult-to-treat diseases, our pipeline is focused on research in therapeutic areas where we believe we have the best opportunity to deliver transformational medicines to patients and protect public health.
Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patient’s lives and to create value for shareholders and our communities.
As pioneers in neuroscience, Biogen has an innovative therapeutic pipeline that aims to reverse disability, repair damage, and address other remaining unmet needs in MS, with the goal of significantly altering the course of MS and preventing disease development and disability progression.
The potential to transform the lives of patients is what drives us at Biogen. As a leading global biotechnology company, we work toward those once-in-a-lifetime moments that could become a historic point in our pursuit of innovative treatments.
Our Products. Below is a list of our company's therapies. The below information is intended for U.S. residents only. For product information for other countries, please visit your country's Biogen affiliate website.
Biogen News Releases and Company Statements. Eisai Completes Rolling Submission to US FDA for LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track Status.
Since 2004 Biogen International has worked with health authorities, regulatory bodies, health care professionals and patient organizations to benefit people living with serious neurological and neurodegenerative diseases.